This inventor holds 1 USPTO granted patent. Top assignee: Sewon Cellontech Co., Ltd.. Active years: 2018.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2018
Title: Min Jung Choi: Innovator in Stem Cell Culturing
Introduction
Min Jung Choi is a notable inventor based in Bucheon, South Korea. He has made significant contributions to the field of stem cell research, particularly in the development of culturing mediums for mesenchymal stem cells. His innovative work has the potential to advance therapeutic applications in regenerative medicine.
Latest Patents
Min Jung Choi holds a patent for a basic culture medium specifically designed for mesenchymal stem cells. This patent, titled "Mesenchymal stem cell basic culturing medium," discloses a medium that enhances the proliferation rate of undifferentiated mesenchymal stem cells derived from adult tissues, such as human marrow and adipose tissue. The medium not only reduces the time taken from collection to mass culturing but also facilitates various differentiations into treating agents for bone-forming cells, cartilage cells, or fat cells. He has 1 patent to his name.
Career Highlights
Min Jung Choi is currently associated with Sewon Cellontech Co., Ltd., where he continues to innovate in the field of cell therapy. His work is pivotal in enhancing the efficiency of stem cell culturing processes, which is crucial for advancing medical treatments.
Collaborations
Min Jung Choi collaborates with talented individuals in his field, including Jun Keun Lee and Ga Ram Kim, who contribute to the research and development efforts at Sewon Cellontech Co., Ltd. Their teamwork fosters an environment of innovation and progress in stem cell technology.
Conclusion
Min Jung Choi's contributions to stem cell research and his innovative patent for a mesenchymal stem cell culturing medium highlight his role as a key inventor in the field. His work promises to impact regenerative medicine significantly.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile